After completing his PhD degree studying transcriptional kinases in yeast, had one goal for his career: to make a difference for human health. Today, he is on the cusp of advancing a promising compound into the drug discovery and development pipeline. If successful, it would become the first targeted treatment for patients with Ewing sarcoma, a rare form of cancer primarily found in children. 鈥淚n my lab, we have been talking about trying to find a drug for 10 years,鈥� says Liu, who is an assistant professor at the University of North Carolina at Chapel Hill. 鈥淭his is the first time for our dream to come true.鈥�
That dream, shaped by more than a decade of research at premier medical research centers, is moving closer to reality thanks in part to a collaboration with Atomwise. Liu won the company鈥檚聽, a program giving academic scientists free access to customized virtual screening of millions or even billions of small molecules through AtomNet庐聽technology. Winners also receive a plate of several dozen small molecule compounds for follow-up functional testing.
At Lineberger, Liu has embraced the center鈥檚 collaborative spirit and teamed up with colleagues studying conditions beyond his own lab鈥檚 focus on kidney and breast cancer. Another scientist told him about Ewing sarcoma, a cancer that forms in bone or nearby tissue, and how patients with this diagnosis still have to rely on conventional chemotherapy and radiation. Liu was intrigued: why were there no targeted therapies available for this cancer? Because the cancer is rare, there had been little drug development effort around it.
But there had been plenty of research into transcriptional events driving Ewing sarcoma, Liu learned. Unfortunately, those events were not druggable. With his background in protein modifications and protein regulation, Liu had a unique perspective on how to target this cancer. By studying a key protein found in all sarcoma cells and in no healthy cells, his team discovered that there were two enzymes required to keep that protein stable. Liu hypothesized that a small molecule inhibitor targeting those enzymes could destabilize those cancerous cells and prevent cancer growth.
That theory led Liu to apply for, and win, an AIMS Award. His protein information was screened in silico against 4 million compounds, with Atomwise鈥檚 AI tool mining the results to highlight the candidates most likely to work as desired. Liu鈥檚 lab received 73 compounds for follow-up testing on Ewing sarcoma cell lines, and one in particular really stood out.
In an iterative round of screening, also to be provided through the AIMS Award, the same protein targets will be run through Atomwise鈥檚 鈥溾�� program, which allows for computational screening of 10 billion compounds. This kind of scale is otherwise out of reach for academic labs. 鈥淲ithout the AIMS Award, we would have had to do some real drug screening, probably with thousands or maybe tens of thousands of compounds,鈥� Liu says. 鈥淎t that level, it鈥檚 really based on luck. This is really time-consuming and expensive.鈥�
At 黑料网, Liu has access to an advanced drug screening facility. He says that the AI-powered results from Atomwise have aligned well with real-world results generated by medicinal chemistry experts at the university. 鈥淓ven without a real structure, the AI can faithfully capture at least 80 to 90 percent of the key structural features of the target,鈥� Liu says.
Now, Liu is working with 黑料网鈥檚 drug discovery unit to optimize the promising compound found through the AIMS Award. 鈥淏efore we received those real compounds,鈥� he says, 鈥淚 never thought we would have a drug.鈥�
About AIMS
罢丑别听, started in 2017, is designed to support promising researchers with resources that will help advance their work. AIMS Awards target research focused on finding solutions for complex human health conditions. To date, Atomwise has funded 5 rounds of AIMS Awards, completing over 100 collaborative projects and accepting over 775 projects into the program.聽聽are accepted anytime.
How to
News courtesy of Atomwise